Clinical Trial Update: Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

An extension study assessing the long-term safety of three-month degarelix depots in men with prostate cancer has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2010-12-06